Stanley Druckenmiller's Duquesne Family Office disclosed new positions in over 40 stocks in its second quarter 13F filing. Notable healthcare investments included 203,618 shares of Rhythm Pharmaceuticals worth $22.6 million and 356,600 shares of Definium Therapeutics worth $16.8 million. Rhythm Pharmaceuticals develops treatments for hypothalamic obesity, currently the only approved drug for this condition. The company estimates approximately 10,000 US patients have acquired hypothalamic obesity, with similar numbers in Europe and 5,000 to 8,000 in Japan. Second-quarter revenue increased 47% year over year, whilst US revenue jumped 38% sequentially. The company remains unprofitable despite revenue growth and held $330.9 million in cash at quarter end, expected to fund operations for at least 24 months.

Definium Therapeutics reported positive results from its Phase III eMERGE study of DT120 ODT for major depressive disorder, achieving what the company described as the largest treatment effect in a Phase III MDD study. The drug showed rapid onset of action at one week, durable benefit through 12 weeks, and favourable tolerability. The biotech completed enrollment in two Phase III studies for generalised anxiety disorder, Voyage and Panorama, with results expected in August and September 2026. Definium strengthened its balance sheet through an upsized public offering generating approximately $758 million, ending Q2 2026 with $1.1 billion in cash. The company reported a net loss of $159 million for Q2 2026, compared to $42.7 million in the prior year period. Operating expenses rose significantly, with R&D spending reaching $48.7 million and general and administrative expenses totalling $26.4 million.

NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical…...